Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-07-18

FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)

View source ↗

Summary

The FDA approved Sandoz's supplemental application for the adalimumab biosimilar ADALIMUMAB-ADAZ. The approval covers multiple inflammatory diseases commonly tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ADALIMUMAB-ADAZ (adalimumab)

Snippet

SUPPL AP for ADALIMUMAB (ADALIMUMAB-ADAZ)